pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
WAINUA (AUTOINJECTOR) · news · pharmadog
← back to WAINUA (AUTOINJECTOR)
News mentioning WAINUA (AUTOINJECTOR)
16
stories
10d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
10d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
15d
BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
biospace
20d
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
biospace
24d
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
24d
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
27d
Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise
biospace
29d
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
biospace
Jul 27, 26
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
Jul 22, 26
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
biospace
Jul 22, 26
Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug
fiercebiotech
Jul 22, 26
Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
biospace
Jul 9, 26
STAT+: Pharmalittle: We’re reading about FDA commissioner contenders, a heart drug failure, and more
stat
Jul 9, 26
STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
stat
Jul 9, 26
Updated: AstraZeneca sinks on unexpected heart drug trial failure
endpoints
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
